The bacteria Bacillus subtilis has been found to prevent α-synuclein build up in C. elegans, offering further support to the idea that the gut microbiome can influence brain activity.
Having previously been demonstrated to allow dopamine replenishment, results of a recent clinical trial suggest nilotinib could be a safe and well-tolerated treatment for individuals with Parkinson’s disease.
Researchers have determined the electrode placement during deep brain stimulation needs to be tailored to the patient as the locations of functional brain networks vary on an individual basis.
A preclinical study in mice has revealed that a specific miRNA could target and modulate the gut microbiome with precision, holding potential as a new treatment option for multiple sclerosis.
Wireless brain–machine interface technology has been utilized to design an exoskeleton for helping a tetraplegic patient move his limbs.
In a large data study, researchers discover that terazosin, a drug typically used to treat enlarged prostate, might be able to slow down neurodegeneration in Parkinson’s disease.
What have been the biggest headlines in industry this week? Take a look at our highlights including positive news about two monoclonal antibodies for relapsing multiple sclerosis and neuromyelitis optica spectrum disorder.
Researchers have identified that α-synuclein plays a role in DNA repair in neurons and that disruption of this function could lead to widespread death of neurons.
This week in industry includes trials on ponesimod for relapsing multiple sclerosis, the Accordion Pill® for Parkinson’s and cannabidiol oral solution for seizures.
Take a look behind the scenes of a recent paper in Biomarkers in Medicine as we ask the author about oligomeric α-synuclein in basal tears of Parkinson’s patients.
